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Summary points
• Antiretroviral therapy (ART) for human immunodeficiency virus (HIV) prevents ill-
ness and death from HIV disease and transmission of HIV infection. To encourage
global scale-up of ART, the Joint UN Program on HIV/AIDS (UNAIDS) issued the
“95-95-95” targets for the HIV “cascade of care.” These targets state that by 2030, 95%
of individuals living with HIV will know their HIV status, 95% of people with diag-
nosed HIV infection will receive ART, and 95% of those taking ART will have achieved
suppression of the virus.
• While tremendous progress has been made toward achieving these targets, substantial
gaps remain. The challenge of closing the final gaps requires reconsideration of the
cascade itself.
• The 95-95-95 HIV care cascade depicts a linear and unidirectional continuum of care
with one starting point (HIV diagnosis) and one ending point (treatment discontina-
tion or death). This simplification of the cascade oversimplifies the complex cycle of
engagement, disengagement, temporary disuptions, reengagement, and transitions in
care experienced by many people living with HIV (PLHIV).
• As the proportion of PLHIV who reinitiate ART after previously starting and stopping
increases, we propose to update the HIV cascade of care to better reflect actual
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Introduction
Since 2014, the global public health community has recognized a set of targets for human
immunodeficiency virus (HIV) known as “90-90-90,” an ambitious plan that called for the
diagnosis of 90% of people living with HIV (PLHIV), antiretroviral therapy(ART) for 90% of
those diagnosed HIV–positive, and viral suppression in 90% of those receiving ART by 2020
[1]. In an effort to end HIV as a global health threat, these initial goals were extended to
achieve “95-95-95” by 2030 [2]. Despite tremendous progress toward achieving these objec-
tives, challenges remain. At the end of 2019, an estimated 81% of PLHIV globally knew their
HIV status, 82% of these were on ART, and 88% of people on ART were virally suppressed,
suggesting an overall viral suppression proportion of just 59% [3].
To understand why countries continue to fall short of achieving the 95-95-95 targets, one
must understand the frequency and circumstances within which people enter and leave HIV
care. While PLHIV continue to disengage from care between HIV diagnosis and ART initia-
tion [4], the recent push for rapid, including same-day, ART initiation, which essentially elimi-
nates losses from care before ART initiation, is leading to a shift of interruptions in care to a
point further down the cascade [5]. This effect becomes even more pronounced during periods
of major service disruption through conflict, natural disaster, or epidemics [6]. Population-
level control of HIV will remain out of reach if many people initiating treatment disengage
from ART for long periods of time, as they will have increased opportunity for viral load fail-
ure, morbidity, mortality [7], development of drug resistance, and viral transmission [8–11].
Cascades have become a common approach to measuring engagement and outcomes of
public health programs and assisting in prioritizing interventions. Most HIV care cascades
depict a linear, unidirectional continuum in which a person enters at the beginning and only
exits upon death or loss to follow-up. This representation has been helpful to compare progress
between geographies and populations and to identify challenges to continuity of care [12].
Multiple studies in sub-Saharan Africa, however, have documented misclassifications of both
the numerators and denominators within these cascades. Some people who appear to have dis-
engaged actually remain in care at the same facility or have “silently” transferred to another
(meaning they do not inform the initial clinic that they are leaving or the receiving clinic that
they were a recipient of care elsewhere). Others have died [7,13–16]. In addition to misclassifi-
cation challenges, linear cascades risk oversimplifying the complex cyclical cycle of entry and
reentry into care experienced by many PLHIV. These simplifications may result in failure to
detect immunosuppression or emergent drug resistance resulting from transient treatment
interruptions and inaccurate prioritization of interventions aimed at improving long-term
retention and viral suppression [17].
experiences of PLHIV. The new cascade makes the cycle of engaging and reengaging
in HIV care both explicit and expected.
• The revised cascade will inform and prioritize efforts by communities, healthcare
workers, implementers, program managers, policymakers, and donors to prevent
missed clinic visits, overcome barriers to care reentry, and minimize onset of advanced
HIV disease. It will also emphasize that morbidity, mortality, and onward transmission
can be minimized by focusing interventions on anticipating, and then reducing, the
duration of gaps in care.
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Many PLHIV start and stop ART multiple times over the course of their lives, creating what
has been termed a “side door” into the cascade through which individuals who have left the
system reenter it [18]. Some people report fear of being treated poorly if they return to care
after an absence [19] and may perceive it as more acceptable to retest and restart ART at a new
facility as a “new” patient rather than facing censure from healthcare staff [20,21]. Routinely
collected medical records in most settings do not adequately document this phenomenon. In
one notable exception, South Africa’s Western Cape Province undertook a pilot that used
unique patient identifiers and digitized routinely collected point-of-care HIV test results to
assess testing and restarts. Within their intervention site, 51% of people who tested HIV–posi-
tive had previously been diagnosed, and 71% of these had previously started ART. In other
words, more than one-third of HIV testers had previously been on ART [22]. This information
was used to highlight the need to redirect resources from expansion of HIV testing to
improved focus on continuity of care.
With an increasing proportion of initiators being non-naive to ART and the growing
implementation of same day ART initiation, we propose the introduction of an HIV cas-
cade of care that better captures the nonlinear HIV journey and defines the numerator
and denominator at each step. This revision can support stakeholders, including Minis-
tries of Health, providers, and donors, to recognize that while treatment interruptions
may be inevitable for some people over a lifetime of HIV treatment, negative public health
and clinical consequences could be minimized by focusing on decreasing gaps in care.
Being “disengaged” or “engaged” is not a final state: It is an interval within the lifetime of a
recipient of care. A cascade that documents actual PLHIV behavior—the cycle of engaging
and reengaging in care—would inform and prioritize efforts intended to prevent missed
clinic visits, overcome barriers to reentry, and minimize onset of advanced HIV disease
[5,23–25].
Proposal for a cyclical cascade
To capture the care pathways of PLHIV, we propose a cyclical cascade as illustrated in Fig 1
and defined in Table 1. Following prior cascades [17], the proposed cascade defines four linear
stages plus a stage of disengagement that is an alternative path after each stage. Reengagement
is represented as a dotted line as it is a transition state between disengagement and resumption
of service delivery.
The primary innovation of the proposed cascade is the inclusion of potential disengage-
ment at each of the four stages and opportunities for reengagement at the first two: (re)diagno-
sis and (re)link. By explicitly capturing PLHIV revolving into and out of each of the stages of
care, it becomes possible to both pose and answer novel questions. While a linear cascade can
describe the stage at which PLHIV are most likely to exit treatment, it cannot answer the fol-
lowing: (1) What are the stages in the revised cascade with the most reentries back into the
health system? (2) What is the frequency of repeat exit and reentry? (3) Which stages most cor-
relate with return without intervention versus as a result of an intervention? (4) What are the
implications of loss/reentry at a given stage on future losses? Failure to answer these questions
can impede our ability to develop effective interventions to support continuity of care and
effectively utilize available resources.
While scale-up of same-day ART initiation in many facility or community settings may
lead to the merging of Stages 1 and 2, the proposed cascade maintains linkage/re-linkage as a
separate intermediate step. We define linkage or “enrollment” as assignment of a unique per-
son number and/or establishment of a medical record with the intention of prescribing ART.
If a person is identified as having reengaged with care or has an existing health system number,
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they may be reassigned their original number and/or record, but, practically speaking, they
will often be assigned a new one. As programs may have different definitions for “enrollment,”
it may be challenging to compare this indicator across countries. However, a localized version
could be used to measure the extent of disengagement that occurs between diagnosis and initi-
ation over time. We are also proposing retention be split into “early” (first six months or time
to first viral load test result) and “long-term” (after first viral load test result or first six months
on ART) as there are important differences in service delivery between these time periods. The
proposed definition for where Stage 3 ends and Stage 4 begins is based on the updated 2021
WHO guidance, which “encourages that the first viral load result be . . . reviewed by 6 months
after initiating ART” [26]. This interval should be adjusted as evidence accumulates or as guid-
ance on timing of first viral load test changes. Clinical outcomes, such as viral load suppres-
sion, are not explicitly included in the cascade as long-term retention in care, the fourth stage
in our cascade, is highly correlated with suppressed viral load [7,27], and our intention is to
better understand PLHIV behavior as it relates to patterns of engagement, not the biological
results of treatment. Finally, the proposed cascade does not identify the facility at which people
return to care or indicate how long they were disengaged. These data points are critical, how-
ever, and will require additional investigations.
Fig 1. Cyclical cascade of HIV care. ART, antiretroviral therapy; HIV, human immunodeficiency virus.
https://doi.org/10.1371/journal.pmed.1003651.g001
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The cyclical cascade can help target interventions
By embracing the cyclical nature of engagement with HIV care, programs can use resources
more effectively. Research can uncover the demographic and clinical characteristics (including
comorbidities), needs, behaviors, perceptions, and preferences of PLHIV most at risk of dis-
engagement and their communities’ influence on their continuum of care. With this informa-
tion, targeted (and, optimally, generalizable and scalable) interventions can be introduced that
will (1) identify people at greatest risk of disengagement and help support their retention in
care (i.e., minimize disengagement); (2) rapidly detect people who appear to have disengaged,
confirm their status, and facilitate their return to care as needed (i.e., reverse disengagement
that has already occurred or identify silent transfers and remove duplicate charts within the
record system); and (3) target different interventions to individuals depending on whether
they have been in a stage of the cascade before. Such work has already been conducted in Zam-
bia [28,29] and South Africa [30] and could provide a foundation for efforts in other settings.
Identifying which PLHIV are at greatest risk of disengagement from within subpopulations
is a high priority. Population HIV impact assessments (PHIAs) in five southern African coun-
tries have reported that among people with nonsuppressed viral load, marriage, female sex,
shorter ART duration, higher CD4 count and alcohol use were associated with higher odds for
interrupted ART [31]. Many may have been women who were offered rapid ART initiation
during an antenatal program following Option B+ guidelines. However, most individuals,
Table 1. Definitions of the stages of the cyclical cascade of HIV care
Stages of the cyclical HIV cascade Definition
Stage 1: HIV+ diagnosis/HIV+ re-diagnosisa ➔ Linked/
relinked
The interval from receiving an HIV–positive diagnosis
to enrollment in an HIV treatment program as a new or
returning client
Stage 2: Linked/relinked ➔ Initiated/reinitiatedb The interval from enrollment in an HIV treatment
program as a new or returning client to receiving ART
Stage 3: Initiated/reinitiated ART➔ Early retention (until
first viral load test result received or maximum of 6
months after ART start)c
The interval from first dose of ART to initial viral load
test result, which the 2021 WHO guidelines strongly
recommend be reviewed by 6 months after initiating
ART [26]
Stage 4: Early retention➔ Long-term retention (beyond
first viral load test, often after 6 months)
The interval from initial viral load test (currently, most
national guidelines recommend after 6 months on
ART) to final disengagement from care and/or death
Disengagementd A gap of >30 days without taking ART
a“HIV+ re-diagnosis” denotes the situation in which a person who is aware of their HIV diagnosis and who has
interrupted care at any point in their treatment journey uses testing as an opportunity to reengage with care. This
usage is distinct from recommendations for people who are HIV–negative to repeat testing at regular intervals
determined by their risk status.
bMany PLHIV may go directly from testing to same day ART initiation (complete Stages 1 and 2 in 1 day). However,
there remains an opportunity for disengaging between Stages 1 and 2 that warrants continuing to define 2 stages
(with self-testing as well as with more traditional testing modalities), at least until there are sufficient data to
demonstrate that no gap exists between these 2 stages.
cIn the future, Stage 3 may decrease in duration if, for example, time to first viral load test is reduced to 4 months
after initiation with new first-line regimens.
dWhile a gap in ART adherence of more than a few days may have clinical consequences and a gap of 7 days in
appointment keeping should prompt tracing efforts, we propose 30 days as an indication of a change in care behavior
significant enough to be considered “disengagement.” This time period may need to be adjusted with
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even within these high-risk groups, are not likely to interrupt treatment. Targeting the entire
population group, without identifying the minority who are truly at risk, is an inefficient use of
resources. For example, “welcome back” programs have been introduced in some settings [33],
but there has been little effort to direct such interventions more precisely toward individuals
most likely to disengage, including those with a history of disengagement.
Populating and using the cyclical cascade
Utilizing the proposed cyclical cascade as a framework for supporting program management
will require data that are challenging to collect at a routine, programmatic level. People who
discontinue care are often difficult to trace, but there are a few accurate reports of the propor-
tions of ART initiators who were previously on treatment that include their characteristics or
reasons for previous default and what it would take for them to return to care [28,33]. Individ-
ual-level data like these that cover the entire cyclical cascade are required to develop and target
interventions that will minimize exit and facilitate reentry along the continuum of care. Popu-
lating the cascade will require multiple data sources, including routine clinical data, surveil-
lance data, and specialized surveys. Of critical importance will be unique national identifiers
that enable programs using electronic medical records (EMRs) to track individuals over time
along their journey and across all the facilities or community-based programs they may attend,
as recommended by WHO [34]. The lack of such identifiers has limited many previous
attempts to understand PLHIV movements within health systems and obstructed attempts to
provide high-quality person-centered care. In an attempt to answer one such question, a recent
analysis of household survey and HIV testing program data across sub-Saharan Africa esti-
mated that “58% of positive tests will have been done on previously diagnosed PLHIV in sub-
Saharan Africa in 2020” [35]. If this trend is further validated, efforts to retain and reengage
people who have interrupted treatment will become a higher yield activity than population-
wide testing to make new HIV diagnoses.
Once data are in hand, interventions can be designed to context in a way that has not
previously been feasible. For example, one HIV program might recognize that retesting for
HIV (Stage 1) is the most acceptable way for PLHIV who have disengaged from care to
reengage and begin to actively encourage it as a pragmatic approach to reinitiating ART.
Another program might find that its major challenge is linkage from diagnosis to treatment
initiation (Stage 2) among young men and conduct further studies to identify critical struc-
tural challenges such as transportation. This program may decide that community-based
ART initiation and dispensing medicines covering longer durations are the most promising
way to address this issue [36]. A third program may identify missed clinic visits during the
first six months after initiation (Stage 3) as the critical predictor of disengagement; these lat-
ter programs could then focus on how to optimize early retention for PLHIV with the char-
acteristics of those most likely to drop out in Stage 3. Further, this new cascade may help
motivate the design of interventions beyond those currently included in WHO guidelines
(Table 2) [37] or described in the published literature [5] as new population needs are
identified.
As depictions of the cascade become more realistic, they will also become more geographi-
cally and population specific. A cyclical cascade can focus attention on exactly who is lost,
when, where, and why—thereby allowing targeted interventions. At the same time, data from
one setting may become even less generalizable than they have been in the past. Facilities that
serve large numbers of migrant workers, for example, are likely to see very different patterns of
disengagement and reengagement than those that serve more settled populations. It will thus
be incumbent on researchers and program evaluators to understand and note the local
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characteristics of PLHIV behavior and tailor recommendations according to best practices,
many of which were defined in a recent review [5].
Finally, an additional benefit of the revised cascade may be that efforts to populate it will
result in identifying a potentially large group of people who have disengaged from and then
reengaged in care but are still counted as “lost” by sites reporting their outcomes. We may find
that ART programs have been more effective at preventing HIV mortality and transmission
than past estimates that relied on linear cascades have implied [18].
Conclusions
HIV programs globally, and their stakeholders and funders, have begun to recognize that the
natural course of HIV care is that many people will, at some point or points, disengage from
treatment as their preferences, needs, and behaviors change. These same PLHIV may then
reengage after a brief or lengthy interval, while a small proportion may never reengage. In this
respect, HIV care is likely similar to care of other chronic diseases. Health systems must be
equipped to recognize and anticipate this revolving door of HIV care and focus on minimizing
the frequency and duration of periods of disengagement. Achieving this shift should start with
development and use of a revised representation of a cascade that recognizes the actual ways
that PLHIV interact with care. Maximizing retention across the cascade will require recogniz-
ing the factors leading to disengagement—structural, clinic based, and individual—and ensur-
ing that they are systematically addressed by providers, communities, and the health system.
While a conventional linear cascade remains useful in identifying obvious programmatic chal-
lenges and tracking progress toward global targets, a cyclical cascade that acknowledges an
individual’s true experience is required to sustain progress and improve outcomes.
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Table 2. WHO evidence-based recommendations and good practice statements to strengthen the cascade.
HIV testing [38] • Demand creation
• Multiple testing approaches (facility-based HTS, community-based HTS, self-testing)
• Provider-assisted referral
• Social network–based approaches
Linkage to care [38] • Streamlined interventions to reduce time between diagnosis and engagement in care,
including (i) enhanced linkage with case management; (ii) support for HIV disclosure;
(iii) patient tracing; (iv) training staff to provide multiple services; and (v) streamlined
and colocated services (moderate-quality evidence)
• Peer support and navigation approaches for linkage
• Quality improvement approaches using data to improve linkage
Initiation of ART
[26,34,37,39]
• Out-of-facility ART initiation
• Rapid ART initiation, including same-day start
• Tailored patient education, counseling, and support to improve uptake of same-day
start
• Task sharing and decentralization
Retention [26,37,39] • Offer of 3–6 monthly clinic visits and ART refills, preferably every 6 months if
feasible
• Package of community-based interventions
• Adherence clubs
• Extra care for high-risk people
• People-centered practices and communication to improve the relationships between
patients and healthcare providers
Reengagement [37] • Tracing and support for reengagement
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